In order to test if there is activity, a phase I/II trial of 30–50 patients would likely be needed to see the response rate as this was sufficient to see activity of lapatinib in patients with metastatic HER2-amplified breast cancers [73]. The gene discussed is ERBB2; the disease is breast carcinoma.